⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30629015 | 0.82 | — | — | |
| SCHEMBL29930619 | 0.82 | — | — | |
| SCHEMBL126608 | 0.82 | — | — | |
| SCHEMBL28170742 | 0.82 | — | — | |
| SCHEMBL27706047 | 0.79 | — | — | |
| SCHEMBL11086015 | 0.79 | — | — | |
| SCHEMBL24611247 | 0.75 | — | — | |
| SCHEMBL29233365 | 0.73 | — | — | |
| SCHEMBL23174790 | 0.73 | — | — | |
| SCHEMBL9876654 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160387-B1 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI SA (FR) | 2014-05-14 | — | — | EP | disclosed |
| US-8598175-B2 | Heteroarylamide pyrimidone derivatives | SANOFI (FR) | 2013-12-03 | — | — | US | disclosed |
| US-8592437-B2 | Heteroarylamide pyrimidone compounds | SANOFI (FR) | 2013-11-26 | — | — | US | disclosed |
| EP-2162443-B1 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI SA (FR) | 2013-07-31 | — | — | EP | disclosed |
| US-8198287-B2 | Substituted heteroaryl pyridopyrimidone derivatives | SANOFI-AVENTIS (FR) | 2012-06-12 | — | — | US | disclosed |
| US-20100087449-A1 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-04-08 | — | — | US | disclosed |
| US-20100081677-A1 | HETEROARYLAMIDE PYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2010-04-01 | — | — | US | disclosed |
| EP-2162443-A2 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Sanofi-Aventis (FR) | 2010-03-17 | — | — | EP | disclosed |
| EP-2160387-A2 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | Sanofi-Aventis (FR) | 2010-03-10 | — | — | EP | disclosed |
| US-20090306088-A1 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2009-12-10 | — | — | US | disclosed |
| EP-2121635-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | Sanofi-Aventis (FR) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008155668-A2 | HETEROARYLAMIDE PYRIMIDONE COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008155666-A2 | HETEROARYLAMIDE-SUBSTITUTED PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SANOFI-AVENTIS (FR) | 2008-12-24 | — | — | WO | disclosed |
| EP-1992624-A1 | Heteroarylamide pyrimidone compounds | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
| EP-1992621-A1 | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases | Sanofi-Aventis (FR) | 2008-11-19 | — | — | EP | disclosed |
| WO-2008078196-A2 | SUBSTITUTED HETEROARYL PYRIDOPYRIMIDONE DERIVATIVES | SANOFI-AVENTIS (FR) | 2008-07-03 | — | — | WO | disclosed |
| EP-1939187-A1 | Substituted heteroaryl pyridopyrimidone derivatives | Sanofi-Aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| EP-1198462-A1 | PROCESS FOR PREPARING A 10,11-METHANODIBENZOSUBERANE DERIVATIVE | ELI LILLY AND COMPANY (US) | 2002-04-24 | — | — | EP | disclosed |
| WO-2000075132-A1 | PROCESS FOR PREPARING A 10,11-METHANODIBENZOSUBERANE DERIVATIVE | ELI LILLY AND COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |